IP Library Granted Patent US 8,877,172
Granted Patent B2
US 8,877,172 · App. 13/463,677 · Granted Nov 4, 2014

Zwitterionic polymer bioconjugates and related methods

Inventors: Shaoyi Jiang (Redmond, WA); Andrew Keefe (Seattle, WA); Hong Xue (Pleasanton, CA)
Assignee: University of Washington through its Center for Commercialization
A61K47/48176A61K38/4826
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,877,172
App. No.
13/463,677
Granted
Nov 4, 2014
Kind
B2
Abstract

Zwitterionic polymer and mixed charge copolymer bioconjugates, methods for making and using the bioconjugates.

Claims (15)

1. A zwitterionic polymer bioconjugate comprising one or more zwitterionic polymers covalently coupled to a biomolecule, wherein the zwitterionic polymer comprises a plurality of repeating units, each repeating unit having the formula:

wherein

R 1 is selected from the group consisting of hydrogen, fluorine, trifluoromethyl, C1-C6 alkyl, and C6-C12 aryl groups;

R 2 and R 3 are independently selected from the group consisting of alkyl and aryl, and taken together with the nitrogen to which they are attached form a cationic center;

L 1 is a linker that covalently couples the cationic center [N + (R 2 )(R 3 )] to the polymer backbone [—(CH 2 —CR 1 ) n —];

L 2 is a linker that covalently couples the anionic center [A(=O)O − ] to the cationic center;

A is C;

M + is a counterion associated with the (A=O)O − anionic center;

X − is a counter ion associated with the cationic center;

n is an integer from 1 to about 10,000; and

the biomolecule is a protein, a nucleic acid, a glycoprotein, a proteoglycan, or a lipid.

2. The conjugate of claim 1 , wherein R 1 , R 2 , and R 3 are independently selected from the group consisting of C1-C3 alkyl.

3. The conjugate of claim 1 , wherein L 1 is selected from the group consisting of —C(═O)O—(CH) n′ and —C(═O)NH—(CH 2 ) n —, wherein n′ is an integer from 1 to 20.

4. The conjugate of claim 1 , wherein L 2 is —(CH 12 ) n″ —, where n″ is an integer from 1 to 20.

5. A composition, comprising the conjugate of claim 1 and a pharmaceutically accepted carrier or diluent.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 14, 2016
From: UNIVERSITY OF WASHINGTON
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 040940/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2012
From: JIANG, SHAOYI; KEEFE, ANDREW; XUE, HONG
To: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Reel/Frame 028842/0184 →
Continuity (3)
Continuation PCTUS2010055886 · Nov 8, 2010
Provisional Application 61259088 · Nov 6, 2009
Related Publication 20120315239A1 · Dec 13, 2012